Doxazosin
Product Images NDC 43353-648

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Doxazosin (NDC 43353-648). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 2mg (43353 647)

Doxazosin Mesylate is a medication available in tablet form, with 90 tablets per container, each containing 2mg of the active ingredient. The tablets should be kept in a place where the temperature is between 20 and 25 degrees Celsius, and should be kept away from the reach of children. The manufacturer of the medication is Mylan Pharmaceuticals Inc, based in Morgantown, WV, and it was repackaged by Aphena Pharma in Cookeville, TN. The batch number for this medication is N 43353-0647-60.*

FDA Label Image

Bottle Label 4mg (43353 648)

This is a description of a medication called Doxazosin Mesylate. It comes in a package of 90 tablets and is manufactured by Mylan Pharmaceuticals Inc in Morgan town, WV. It has a batch number of 2 and a lot number of 43353-0648-60. The medication should be stored between 20-25 degrees Celsius and kept out of reach of children. It should also be dispersed in its original container, which is certified by USP standards. The medication is re-packaged by Aphena Pharma in Cookesville, TN 38506.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Structural Formula (A7293678 9b1b 4102 9a79 1000d853dc16 01)

FDA Label Image

Figure 1 (A7293678 9b1b 4102 9a79 1000d853dc16 02)

This appears to be a figure or graph depicting the mean change in total symptom score and mean increase in maximum urinary flow rate from baseline over a duration of treatment in weeks. No further information or context is available.*

FDA Label Image

Table 1 (A7293678 9b1b 4102 9a79 1000d853dc16 03)

This appears to be a tabular presentation of data from three studies involving the use of doxazosin to treat hypertension associated with benign prostatic hypertrophy (BPH). The studies involved titration to maximum dose, titration to fixed dose for 14 weeks, and titration to fixed dose for 12 weeks, respectively. The effectiveness of treatment was evaluated using the maximum flow rate and symptom score of patients. The fourth column contains numerical values for mean baseline and baseline change. The output shows some inaccuracies in the numbers making it difficult to draw precise conclusions.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.